Inhibition of immune-mediated meningoencephalitis in persistently Borna disease virus-infected rats by cyclosporine A.
In rats persistently infected with Borna disease virus (BDV), severe neurologic disorders and occasional death are the consequences of a T cell-mediated immunopathologic reaction in the brain. It is shown here that the pathologic alterations in the brain and as a result, Borna Disease (BD) can be prevented if animals are treated with the immunosuppressive drug cyclosporine A (CSA) under the following optimal conditions: greater than or equal to 25 mg/kg/day of CSA, started before infection and given for 4 wk. Rats treated with lower doses of CSA, for shorter periods or after infection displayed encephalitic lesions and developed BD. When CSA treatment was begun even as early as 1 day after infection, encephalitis and disease were not influenced. Immune spleen cells passively transferred into CSA-treated rats induced the disease in the recipients, whereas lymphoid cells from CSA-treated rats did not induce BD in infected cyclophosphamide-treated recipients. Antibodies were not involved in BD because rats treated with CSA revealed an inhibition of the synthesis of virus-specific antibodies for all regimens of treatment used (whether successful in preventing BD or not). After i.v. challenge of CSA-treated healthy rats with BDV, antiviral antibodies at low titers could be induced in some animals; however, no encephalitis or disease symptoms could be observed at any time after infection. The same was true for rats reinfected intracerebrally with BDV after discontinuation of CSA. These results support the hypothesis that unresponsiveness and even tolerance can be induced by CSA in the presence of the foreign Ag, demonstrating the beneficial effect of this immunosuppressive drug during a persistent viral infection.
Stitz
L
L
Institute für Virologie, Justus-Liebig-Universität Giessen, F.R.G.
Soeder
D
D
Deschl
U
U
Frese
K
K
Rott
R
R
D000818:Animals; D001890:Borna Disease / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D003524:Cyclosporins / Q000627:therapeutic use*; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D007116:Immunization, Passive; D007117:Immunization, Secondary; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008590:Meningoencephalitis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D011917:Rats, Inbred Lew; D013154:Spleen / Q000637:transplantation; D013997:Time Factors
D003524:Cyclosporins